These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 15170928

  • 1. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
    Wolfe F, Zhao S, Pettitt D.
    J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
    [Abstract] [Full Text] [Related]

  • 2. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F, Michaud K, Burke TA, Zhao SZ.
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [Abstract] [Full Text] [Related]

  • 3. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 4. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 04; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 04; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 7. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Oct 04; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec 04; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 12. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D.
    J Rheumatol; 2002 Mar 04; 29(3):467-73. PubMed ID: 11908558
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 04; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 15. New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study.
    Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT.
    Ann Pharmacother; 2007 Jun 04; 41(6):937-43. PubMed ID: 17488830
    [Abstract] [Full Text] [Related]

  • 16. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV, Burke TA, McCoy MA, Trotter JP.
    Clin Ther; 2003 Feb 04; 25(2):647-62. PubMed ID: 12749519
    [Abstract] [Full Text] [Related]

  • 17. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
    Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
    Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D.
    J Rheumatol; 2002 May 09; 29(5):1015-22. PubMed ID: 12022317
    [Abstract] [Full Text] [Related]

  • 20. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN, Callaghan R, Allen ME, Rowe IF.
    Rheumatology (Oxford); 2005 Jul 09; 44(7):921-4. PubMed ID: 15827035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.